This combined research led to a total placement in the top 400 in 2018 when it was discovered that disinhibition of adipose tissue lipoprotein lipase is a novel therapeutic modality of ANGPTL8, to enhance adipose lipid uptake and treat non-alcoholic fatty liver disease and insulin resistance [58]. The gene discussed is LPL; the disease is metabolic dysfunction-associated steatotic liver disease.